The -13.88% Decline of MDxHealth SA’s (MDXH) Stock in the Past Quarter

In the past week, MDXH stock has gone up by 17.67%, with a monthly decline of -19.95% and a quarterly plunge of -25.63%. The volatility ratio for the week is 10.26%, and the volatility levels for the last 30 days are 10.16% for MDxHealth SA The simple moving average for the past 20 days is 3.72% for MDXH’s stock, with a -10.71% simple moving average for the past 200 days.

Is It Worth Investing in MDxHealth SA (NASDAQ: MDXH) Right Now?

Company’s 36-month beta value is 0.50.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for MDXH is 14.84M, and currently, short sellers hold a 0.16% ratio of that floaft. The average trading volume of MDXH on April 03, 2024 was 78.97K shares.

MDXH) stock’s latest price update

MDxHealth SA (NASDAQ: MDXH)’s stock price has soared by 13.57 in relation to previous closing price of 2.58. Nevertheless, the company has seen a gain of 17.67% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-06 that MDxHealth SA (NASDAQ:MDXH ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Michael McGarrity – CEO Ron Kalfus – CFO Conference Call Participants Andrew Brackmann – William Blair Thomas Vranken – KBC Securities Jason Bednar – Piper Sandler Mark Massaro – BTIG Operator Good afternoon, ladies and gentlemen and welcome to the MDxHealth Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Analysts’ Opinion of MDXH

Many brokerage firms have already submitted their reports for MDXH stocks, with TD Cowen repeating the rating for MDXH by listing it as a “Outperform.” The predicted price for MDXH in the upcoming period, according to TD Cowen is $7 based on the research report published on May 31, 2023 of the previous year 2023.

Oppenheimer, on the other hand, stated in their research note that they expect to see MDXH reach a price target of $18. The rating they have provided for MDXH stocks is “Outperform” according to the report published on July 18th, 2022.

MDXH Trading at -12.82% from the 50-Day Moving Average

After a stumble in the market that brought MDXH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.85% of loss for the given period.

Volatility was left at 10.16%, however, over the last 30 days, the volatility rate increased by 10.26%, as shares sank -19.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.02% lower at present.

During the last 5 trading sessions, MDXH rose by +17.67%, which changed the moving average for the period of 200-days by -25.26% in comparison to the 20-day moving average, which settled at $2.79. In addition, MDxHealth SA saw -25.63% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for MDXH

Current profitability levels for the company are sitting at:

  • -0.47 for the present operating margin
  • 0.6 for the gross margin

The net margin for MDxHealth SA stands at -0.75. The total capital return value is set at -0.26.

Based on MDxHealth SA (MDXH), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -2.59.

Currently, EBITDA for the company is -32.99 million with net debt to EBITDA at -0.31. When we switch over and look at the enterprise to sales, we see a ratio of 1.38. The receivables turnover for the company is 7.43for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.95.

Conclusion

In a nutshell, MDxHealth SA (MDXH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts